Literature DB >> 19228073

Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.

Jerome Deval1.   

Abstract

Over the past 20 years, nucleoside analogues have constituted an arsenal of choice in the fight against HIV, hepatitis B and C viruses, and herpesviruses. Classical antiviral nucleosides such as zidovudine act as obligate chain terminators. Once incorporated as monophosphates into the viral nucleic acid, they immediately block the progression of the polymerase as a result of their lack of a reactive 3'-hydroxyl (3'-OH) group. This review explores beyond the paradigm of obligate chain termination, from a structural and a mechanistic perspective, the strategy of inhibiting viral polymerases (RNA- and DNA-dependant) with nucleoside analogues containing a 3'-OH group. Depending on their mechanism of action, these molecules typically fall into the following three categories: (i) delayed chain terminators; (ii) pseudo-obligate chain terminators; or (iii) mutagenic nucleosides. Delayed chain terminators (i.e. penciclovir, cidofovir and entecavir) block the polymerase at an internal position within the viral nucleic acid, whereas R7128 and the 4'C substituted nucleosides do not permit subsequent incorporation events. Ribavirin, 5-hydroxydeoxycytidine and KP1461 are not chain terminators. Instead, they inhibit viral replication after mispairing with the template base, resulting in random mutations that are often lethal. Finally, brivudine, clevudine and other L-nucleosides have unique or yet to be defined mechanisms of inhibition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228073     DOI: 10.2165/00003495-200969020-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  53 in total

1.  2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.

Authors:  Hiroshi Ohrui
Journal:  Chem Rec       Date:  2006       Impact factor: 6.771

Review 2.  Effects of nucleotides and nucleotide analogue inhibitors of HIV-1 reverse transcriptase in a ratchet model of polymerase translocation.

Authors:  Matthias Götte
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 3.  Ribavirin's antiviral mechanism of action: lethal mutagenesis?

Authors:  Shane Crotty; Craig Cameron; Raul Andino
Journal:  J Mol Med (Berl)       Date:  2001-12-04       Impact factor: 4.599

4.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.

Authors:  S Crotty; D Maag; J J Arnold; W Zhong; J Y Lau; Z Hong; R Andino; C E Cameron
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

5.  Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication.

Authors:  Lieven J Stuyver; Tamara R McBrayer; Phillip M Tharnish; Jeremy Clark; Laurent Hollecker; Stefania Lostia; Tammy Nachman; Jason Grier; Matthew A Bennett; Meng-Yu Xie; Raymond F Schinazi; John D Morrey; Justin L Julander; Phillip A Furman; Michael J Otto
Journal:  Antivir Chem Chemother       Date:  2006

6.  Inhibition of hepatitis B virus polymerase by entecavir.

Authors:  David R Langley; Ann W Walsh; Carl J Baldick; Betsy J Eggers; Ronald E Rose; Steven M Levine; A Jayne Kapur; Richard J Colonno; Daniel J Tenney
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 7.  Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.

Authors:  Marco Vignuzzi; Jeffrey K Stone; Raul Andino
Journal:  Virus Res       Date:  2005-02       Impact factor: 3.303

8.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

Review 9.  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin.

Authors:  Julia Watson
Journal:  Curr Opin Investig Drugs       Date:  2002-05

10.  Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase.

Authors:  Jaehoon Shim; Gabry Larson; Vicky Lai; Suhaila Naim; Jim Zhen Wu
Journal:  Antiviral Res       Date:  2003-05       Impact factor: 5.970

View more
  24 in total

1.  Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

2.  The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase.

Authors:  K A Kirby; K Singh; E Michailidis; B Marchand; E N Kodama; N Ashida; H Mitsuya; M A Parniak; S G Sarafianos
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2011-02-12       Impact factor: 1.770

3.  Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.

Authors:  Zhinan Jin; Kathryn Tucker; Xiaoyan Lin; C Cheng Kao; Ken Shaw; Hua Tan; Julian Symons; Ishani Behera; Vivek K Rajwanshi; Natalia Dyatkina; Guangyi Wang; Leo Beigelman; Jerome Deval
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Authors:  Andrew D Huber; Eleftherios Michailidis; Megan L Schultz; Yee T Ong; Nicolin Bloch; Maritza N Puray-Chavez; Maxwell D Leslie; Juan Ji; Anthony D Lucas; Karen A Kirby; Nathaniel R Landau; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

5.  9-(2'-Deoxy-2'-Fluoro-β-d-Arabinofuranosyl) Adenine Is a Potent Antitrypanosomal Adenosine Analogue That Circumvents Transport-Related Drug Resistance.

Authors:  Farahnaz Ranjbarian; Munender Vodnala; Khalid J H Alzahrani; Godwin U Ebiloma; Harry P de Koning; Anders Hofer
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.

Authors:  Zhi-Gang Jiang; Jeffrey Cohen; Leslie J Marshall; Eugene O Major
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

7.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

8.  Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.

Authors:  Hidehiro Sangawa; Takashi Komeno; Hiroshi Nishikawa; Atsushi Yoshida; Kazumi Takahashi; Nobuhiko Nomura; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

9.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

10.  Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

Authors:  Sunwen Chou
Journal:  Antiviral Res       Date:  2021-09-21       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.